Effects of an EGFR-binding affibody molecule on intracellular signaling pathways

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 967-972

  Nordberg, E ^a   Ekerljung, L ^a   Sahlberg, S H ^a   Carlsson, J ^a   Lennartsson, J ^b   Glimelius, B ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

A 431; Affibody; Akt; Epithelial growth factor receptor; Erk; Signaling; U 343

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; Z EGFR 955 2;

ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; CANCER CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLIOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INTRACELLULAR SPACE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIGANDS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 77749299225     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000576     Document Type: Article

References (25)

1. Bublil EM and Yarden Y: The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19: 124-134, 2007.
2. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005.
3. Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11: 689-708, 2004.
4. Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913, 2004.
5. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006.
6. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107: 1207-1218, 2006.
7. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003.
8. Dutta PR and Maity A: Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 254: 165-177, 2007.
9. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A and Paradiso A: The complexity of targeting EGFR signaling in cancer: from expression to turnover. Biochim Biophys Acta 1766: 120-139, 2006.
10. Citri A and Yarden Y: EGF-ERBB signaling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
11. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
12. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J and Baselga J: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10: 6487-6501, 2004.
13. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M and Nygren PA: Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15: 772-777, 1997.
14. Steffen AC, Orlova A, Wikman M, Nilsson FY, Stahl S, Adams GP, Tolmachev V and Carlsson J: Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 33: 631-638, 2006.
15. Baum R, Orlova A, Tolmachev V and Feldwisch J: A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer. First time in human study using an Indium-111-or Gallium-68-labeled molecule. Eur J Nucl Med Mol Imaging 33: 91-92, 2006.
16. Baum R, Tolmachev V and Feldwisch J: Receptor PET/CT and SPECT using an affibody molecule for targeting and molecular imaging of HER2 positive cancer in animal xenografts and human breast cancer patients. J Nucl Med 47 (Suppl 1): 108, 2006.
17. 2, in EGFR expressing tumour cells. Oncol Rep 19: 853-857, 2008.
18. Nordberg E, Friedman M, Göstring L, Adams GP, Brismar H, Nilsson FY, Ståhl S, Glimelius B and Carlsson J: Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 34: 609-618, 2007.
19. Westermark B, Magnusson A and Heldin CH: Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res 8: 491-507, 1982.
20. Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M and Ronnstrand L: Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18: 5546-5553, 1999.
21. Ruiter GA, Verheij M, Zerp SF, Moolenaar WH and Van Blitterswijk WJ: Submicromolar doses of alkyllyso-phospholipids induce rapid internalization, but not activation, of epidermal growth factor receptor and concomitant MAPK/ERK activation in A431 cells. Int J Cancer 102: 343-350, 2002.
22. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM and Moasser MM: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441, 2007.
23. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK and Bunn PA Jr: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11: 795-805, 2005.
24. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
25. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.